Abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting found persistent ovarian cancer ...

Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian cancer.

Ovarian cancer remains the leading cause of death among cancers affecting the female reproductive system, largely because ...

“This work adds a critical piece to the puzzle of why ovarian cancer is so aggressive and has such poor outcomes. While the immune system is naturally equipped to detect and destroy cancer cells, this ...

"This work adds a critical piece to the puzzle of why ovarian cancer is so aggressive and has such poor outcomes. While the immune system is naturally equipped to detect and destroy cancer cells ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

New research led by Irish scientists has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body's immune response in advanced ovarian cancer.

The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.

Discussing ‘cure’ may risk oncologists’ credibility, should a patient’s ovarian cancer recur,” researchers wrote.